| Literature DB >> 31061816 |
Parastoo Mojtahed Zadeh-Ardabili1, Sima Kianpour Rad2.
Abstract
Although inflammation is a reactive to injurious stimuli and considered as beneficial process in body, but it causes some discomforts, such as pain. Murine dietary contains appreciable amounts of fatty acids and antioxidants which encourages researchers to focus on their potential therapeutic effects. This study is aimed to examine the analgesic and anti-inflammatory activity of Neptune krill oil (NKO) and fish oil (FO) in rodent model which are two well-known sources of rich content of n-3 polyunsaturated fatty acids (n-3 PUFAs), mostly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). NKO and FO were used at the same dose of 500 mg and also balanced at similar doses of EPA: 12 in NKO vs. 12 in FO wt%, DHA: 7 NKO vs. 8 FO wt%. Application of NKO and FO in acetic acid-induced writhing effect, hot plate, and formalin induced test, indicated the nociceptive activity of the two tested drugs in comparison with normal saline. Also, the anti-inflammatory effect of these supplements was confirmed by carrageenan test. Analysis of cytokines levels in the blood samples of the mice after induction inflammation by carrageenan indicated decreased levels of those proteins compared to that in the normal groups. Both tested drugs, effectively could reduce severe inflammation and pain in rodents in comparison with the references drugs (depends on the tests); however, NKO was found to be more effective.Entities:
Keywords: Anti-inflammation; Anti-nociceptive; DHA; EPA; Fish oil; IL-6; Neptune krill oil; TNF-α; n-3 PUFAs
Year: 2019 PMID: 31061816 PMCID: PMC6488718 DOI: 10.1016/j.btre.2019.e00341
Source DB: PubMed Journal: Biotechnol Rep (Amst) ISSN: 2215-017X
NKO and FO nutraceutical products compared in this study. Subsamples from two separate patches of each product were pooled for phospholipids, triglycerides, DHA and EPA analysis.
| Supplement Fact | Neptune Krill oil (NKO™),500 mg Patch NO: 060822 | Fish oil (Nature's Made ®), 500 mg Patch NO: 031604026622 |
|---|---|---|
| Omega-3 fatty acids, mg | 115 (23 g/100 g) | – |
| Eicosapentaenoic Acid (EPA), mg | 60 (12 g/100 g) | 90 (12 g/100 g) |
| Docosahexaenoic Acid (DHA), mg | 35(7 g/100 g) | 60 (8 g/100 g) |
| Phospholipids, mg | 195(39 g/100 g) | – |
| Triglycerides, mg | – | 150 (18.75 g/100 g) |
| Esterified Astaxanthin, mcg | 375(0.075 g/100 g) | – |
Effects of NKO and FO on carrageenan (0.1%)-induced paw edema.
| Treatment | Dose | Paw volume (ml) | ||||
|---|---|---|---|---|---|---|
| Time | ||||||
| 0hr | 1 hr | 2hr | 3hr | |||
| Control (Na.CMC) | 0.1 ml/mice,ip | 0.6 ± 0.02 | 0.85 ± 0.04 | 0.9 ± 0.02 | 0.94 ± 0.01 | |
| Reference | ||||||
| (Indomethacin) | 10 mg/kg,ip | 0.62 ± 0.04 | 0.47 ± 0.01**(44.7) | 0.41 ± 0.01 | 0.4 ± 0.0 | |
| FO | 500(mg) Orally | 0.64 ± 0.02 | 0.75 ± 0.01 | 0.58 ± 0.04 | 0.61 ± 0.01 | |
| NKO | 500(mg) (orally) | 0.61 ± 0.02 | 0.68 ± 0.03 | 0.49 ± 0.04 | 0.53 ± 0.02 | |
The values in the parentheses indicate the percentage of inhibition. Values are mean ± SD of six samples in each group. * Significant ns – Not significant Inhibition of carrageenan-induced mouse paw edema by indomethacin, NKO and FO measured at 1, 2, 3 h, after carrageenan injection.
=p < 0.05.
=p < 0.01.
Fig. 1Inhibition percentage of paw volume in carrageenan induced-inflammation.
Fig. 2Levels of IL-6 in the serum of animals with carrageenan induced-inflammation before and after treatments.
Fig. 3Levels of TNF-α in the serum of animals with carrageenan induced-inflammation before and after treatments.
Fig. 4FO and NKO did not have any analgesic effect using formalin test in mice.
Effects of NKO and FO on writhing induced by acetic acid and change in latency time in hot-plate in mice#, *=p < 0.05,## and **=p < 0.01 and ***=p < 0.001. #=different value effect between FO and NKO.
| Hot plate test mean reaction time (h ± SD) | |||||||
|---|---|---|---|---|---|---|---|
| Groups | Dose | 0 | 1 hr | 2hr | 3hr | Number of writhing | % inhibition |
| Control (Na.CMC) | 0.2 ml/mice, ip | 2.58 ± 0.02 | 2.28 ± 0.02 | 2.62 ± 0.03 | 2.66 ± 0.04 | 40 | 0 |
| Reference | 100 | 2.58 ± | 6.98 ± 0.0 | 8.11 ± 0.0 | 7.51 ± 0.0 | 12*** | 70 |
| Aspirin | 0.02 | 1** | 0** | 1** | |||
| 10 | (44.1) | (51.3) | (47.5) | ||||
| Pentazocine (for hot plate) | (mg/kg),ip | ||||||
| FO | 500(mg) | 2.41 ± 0.01 | 3.4 ± 0.01*(24.1) | 5.49 ± 0.01**(39) | 3.01 ± 0.01**(21.2) | 31* | 22.5 |
| NKO | 500 | 2.48 ± 0.01 | 3.82 ± 0.02*(23.4) | 6.53 ± 0.02**(44.1) | 3.52 ± 0.02 | 20**# | 50## |
The values in the parentheses indicate the percentage of inhibition. Values are mean ± SD of six samples in each group. * Significant ns – Not significant Inhibition of hot plate test by Pentazocine and writhing number in acetic acid induced writhing by Aspirin, NKO and FO measured at 1, 2 and 3 h in hot plate assay.